Weight LossClinical Trials
Orforglipron
Also known as: LY3502970
The first oral non-peptide GLP-1 receptor agonist. A daily pill achieving near-injectable weight loss results without needles.
Reviewed by Dr. Sarah Mitchell, PharmD, BCPS
Lead Researcher · 12+ years in peptide therapeutics
Half-Life
~25–50 hours
Typical Dose
36–45 mg daily
Administration
Oral
Mechanism of Action
Small molecule that survives stomach acid and activates GLP-1 receptors orally, eliminating the need for injection-based delivery.
Key Research Areas
weight lossGLP-1oralpillneedle-free
Frequently Asked Questions
What is Orforglipron?▾
The first oral non-peptide GLP-1 receptor agonist. A daily pill achieving near-injectable weight loss results without needles.
How does Orforglipron work?▾
Small molecule that survives stomach acid and activates GLP-1 receptors orally, eliminating the need for injection-based delivery.
What is the recommended dosage for Orforglipron?▾
The typical research dosage is 36–45 mg daily, administered via Oral. Dosage protocols vary by study and should be determined by a qualified healthcare professional.
What is the half-life of Orforglipron?▾
The half-life of Orforglipron is approximately ~25–50 hours. This affects dosing frequency and timing in research protocols.
Is Orforglipron FDA approved?▾
Orforglipron is currently classified as "Clinical Trials" and is not FDA approved for general use. It is available for research purposes or through compounding pharmacies depending on your jurisdiction.
Research Disclaimer
The information provided about Orforglipron is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare professional before starting any peptide protocol. Products discussed have not been evaluated by the FDA unless explicitly noted.